Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® bei Kindern von 5 bis unter 12 Jahren in der Europäischen Union
25 nov. 2021 07h30 HE
|
BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 25. November 2021—Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union
25 nov. 2021 07h30 HE
|
BioNTech SE
NEW YORK and MAINZ, Germany, November 25, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use...
BioNTech erhält FDA-Fast-Track-Status für FixVac-Kandidaten BNT111 bei fortgeschrittenem Melanom
19 nov. 2021 06h30 HE
|
BioNTech SE
MAINZ, Deutschland, 19. November 2021 — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (Food and Drug Administration,...
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
19 nov. 2021 06h30 HE
|
BioNTech SE
MAINZ, GERMANY, November 19, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111,...
Global RNA Targeting Small Molecules Therapeutics Market Research Report 2021 with Analysis & Forecasts to 2030
09 nov. 2021 06h18 HE
|
Research and Markets
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RNA Targeting Small Molecules Therapeutics Market by Type of Target Molecule, Type of Approach, Target Indication, Target Therapeutic Area, Route of...
AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer
01 nov. 2021 09h03 HE
|
AGC Biologics
Seattle, Nov. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Jean-Baptiste Agnus has been...
Pfizer und BioNTech erhalten die erste US-Notfallzulassung für COVID-19-Impfung von Kindern im Alter von 5 bis 11 Jahren durch die FDA
29 oct. 2021 17h45 HE
|
BioNTech SE
Die Notfallzulassung (Emergency Use Authorization, „EUA“) basiert auf klinischen Daten, die ein vorteilhaftes Sicherheitsprofil und einen hohen Impfschutz von 90,7 % bei Kindern im Alter von 5 bis 11...
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
29 oct. 2021 17h45 HE
|
BioNTech SE
Emergency Use Authorization (EUA) is supported by clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 through 11 years of age during a period when Delta...
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
26 oct. 2021 18h19 HE
|
BioNTech SE
Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 years of age during a period when Delta was the prevalent strain10-µg...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
21 oct. 2021 06h45 HE
|
BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...